Brief: Curis Announces Additional Encouraging Clinical Data From Takeaim Leukemia Study Of Emavusertib (CA-4948) In Monotherapy R/R Aml And Hrmds
12/12/2022 15:58
Curis Inc CRIS.O :
* CURIS ANNOUNCES ADDITIONAL ENCOURAGING CLINICAL DATA FROM
TAKEAIM LEUKEMIA STUDY OF EMAVUSERTIB (CA-4948) IN MONOTHERAPY
R/R AML AND HRMDS
* CURIS-POSITIVE INITIAL DATA OF EMAVUSERTIB IN COMBINATION
WITH
VENETOCLAX IN PATIENTS WITH AML OR HRMDS,ENROLLED IN PHASE 1B OF
TAKEAIM LEUKEMIA STUDY
* CURIS-CONTINUE TO ENROLL PATIENTS AT 200MG DOSE LEVEL,
PLAN TO
DISCUSS WITH U.S. FDA, RECOMMENDED PHASE 2 DOSE IN MID-2023 FOR
TAKEAIM LEUKEMIA STUDY
Source text for Eikon: ID:nPnb9sMhHa
Further company coverage: CRIS.O
Recent news on Curis
See all newsCuris Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Curis Announces Pricing Of $5.6 Million Public Offering
Curis Inc expected to post a loss of $7.84 a share - Earnings Preview
Curis Inc expected to post a loss of $7.47 a share - Earnings Preview
Brief: Curis Doses First Five Patients In Takeaim Cll Study